Comparative Pharmacology
Head-to-head clinical analysis: ERYMAX versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYMAX versus WYAMYCIN E.
ERYMAX vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic